ATAI Projected Dividend Yield

Ord/ATAI Life Sciences NV ( NASDAQ : ATAI )

ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company developing treatments for mental health disorders. Its lead compounds include PCN-101, a subcutaneous R-ketamine for treatment-resistant depression; RL-007, a modulator for cognitive impairment in schizophrenia; DMX-1002, an oral ibogaine for opioid use disorder; GRX-917, an oral deuterated etifoxine for generalized anxiety disorder; and NN-101, an intranasal N-acetylcysteine for mild traumatic brain injuries. Other candidates include VLS-01 for depression and EMP-01 for PTSD.

23 YEAR PERFORMANCE RESULTS